We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Rebuffs Merck’s Keytruda for Lung Cancer Treatment
NICE Rebuffs Merck’s Keytruda for Lung Cancer Treatment
The UK’s price watchdog is not recommending reimbursement for Merck’s Keytruda for the treatment of advanced or metastatic lung cancer in patients who have had at least one previous chemotherapy regimen.